GSK set out plans on Wednesday to turn its consumer healthcare arm into a separately listed company, in a move that will deliver an 8 billion pound ($11 billion) windfall and other financial benefits for its...
Reaction to GSK’s plan to spin off its consumer healthcare business
GSK set out plans on Wednesday to turn its consumer healthcare business into a separately listed company, aiming to strengthen drug development at its pharmaceuticals business with an 8 billion pound ($11 billion)...
Ipca Labs acquires 13.09% stake in Trophic Wellness for Rs 21.20 cr
Drug firm Ipca Laboratories on Friday said it has acquired additional 13.09 per cent stake in Trophic Wellness Pvt Ltd for a cash consideration of Rs 21.20 crore, making it a subsidiary of the company. The company has...
Morphosys to acquire Constellation Pharmaceuticals in $1.7 billion deal
Morphosys on Wednesday said it will acquire U.S. cancer specialist Constellation Pharmaceuticals in a $1.7 billion deal that will enable the German biotech firm to add two final-stage cancer drugs to its portfolio...
UK pharma group Vectura agrees $1.4 billion takeover by Carlyle
Vectura Group, a British pharmaceutical company focused on inhaled medicines, said on Wednesday it had agreed a 958 million pound ($1.36 billion) takeover by global investment firm The Carlyle Group. Shareholders will...
Shilpa Medicare ties up with Dr Reddy’s for production of Sputnik V vaccine
Shilpa Medicare Limited has tied up with Dr Reddy’s Laboratories Limited (DRL) for the production of Sputnik V vaccine. The company on Monday announced that its whole owned subsidiary Shilpa Biologicals (SBPL) has...
Sackler-owned Mundipharma seeks bids for China unit in over $1 billion deal -sources
Drugmaker Mundipharma International Ltd，owned by the billionaire American Sackler family has kicked off the sale of its China unit in a deal that could fetch more than $1 billion, people familiar with the situation told...
Takeda buys epilepsy treatment rights from Ovid for up to $856 million
Takeda Pharmaceutical Co will spend as much as $856 million to secure global rights from Ovid Therapeutics Inc to an experimental drug being developed to treat rare epilepsy, the companies said on Wednesday. Takeda will...
AstraZeneca has sold its stake in Moderna for more than $1 billion: Report
AstraZeneca Plc has sold its 7.7% stake in Moderna Inc for more than $1 billion after the U.S. biotechnology company’s shares soared on the back of its coronavirus vaccine breakthrough, The Times reported. The...
Merck agrees $1 billion deal with Debiopharm for head and neck cancer drug
Germany’s Merck KGgA said on Monday it has agreed to pay Swiss biotech Debiopharm up to 900 million euros ($1.08 billion) to develop and commercialise Xevinapant for head and neck cancer. Under the terms of the...
Government has decided to close 2 pharma PSUs, disinvest other 3: Gowda
The government has decided to close two pharma public sector undertakings and disinvest the other three, Parliament was informed on Tuesday. “The Department of Pharmaceuticals has five public sector undertakings...
Glenmark board to meet this week to consider buyback for Singapore-listed FCCBs
Glenmark Pharmaceuticals today said its board will meet later this week to consider buyback of its Singapore-listed foreign currency convertible bonds (FCCBs). “…a meeting of the Board of Directors of...
